Alkermes (ALKS) Current Deferred Revenue (2011 - 2025)
Alkermes (ALKS) posted quarterly Current Deferred Revenue of $578000.0 for Q2 2025, down 82.54% year-over-year from $3.3 million in Q2 2024, and down 64.08% quarter-over-quarter from $1.6 million in Q1 2025.
Alkermes (ALKS) Current Deferred Revenue (2011 - 2025) Analysis & Trends
Alkermes (ALKS) has reported Current Deferred Revenue for 15 consecutive years, with $578000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Current Deferred Revenue fell 82.54% year-over-year to $578000.0; the TTM figure through Jun 2025 stood at $578000.0 (down 82.54% YoY), while the FY2024 annual figure was $1.2 million, down 73.84% from the prior year.
- Current Deferred Revenue slipped to $578000.0 in Q2 2025 per ALKS's latest filing, from $1.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $22.7 million in Q1 2021 and bottomed at $578000.0 in Q2 2025.
- Historically, Current Deferred Revenue has averaged $9.1 million across 5 years, with a median of $6.0 million in 2023.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue retreated 18.98% — and 2025, when it plunged 82.54%.
- Alkermes' Current Deferred Revenue stood at $17.8 million in 2021, then tumbled by 39.98% to $10.7 million in 2022, then slumped by 55.38% to $4.8 million in 2023, then tumbled by 73.84% to $1.2 million in 2024, then slumped by 53.72% to $578000.0 in 2025.
- Business Quant data shows ALKS's Current Deferred Revenue at $578000.0 in Q2 2025, $1.6 million in Q1 2025, and $1.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 578,000.00 |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 4.57 Mn |
| Dec 31, 2023 | 4.78 Mn |
| Sep 30, 2023 | 4.98 Mn |
| Jun 30, 2023 | 5.67 Mn |
| Mar 31, 2023 | 6.41 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | 8.64 Mn |
| Jun 30, 2022 | 13.76 Mn |
| Mar 31, 2022 | 14.85 Mn |
| Dec 31, 2021 | 17.83 Mn |
| Sep 30, 2021 | 19.27 Mn |
| Jun 30, 2021 | 20.80 Mn |
| Mar 31, 2021 | 22.67 Mn |
| Dec 31, 2020 | 23.91 Mn |
| Sep 30, 2020 | 25.79 Mn |